These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 3717812)

  • 21. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group.
    Friedenberg WR; Rue M; Blood EA; Dalton WS; Shustik C; Larson RA; Sonneveld P; Greipp PR
    Cancer; 2006 Feb; 106(4):830-8. PubMed ID: 16419071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD).
    Bladé J; San Miguel J; Sanz-Sanz MA; Alcalá A; Hernández JM; Martínez M; García-Conde J; Moro J; Ortega F; Fontanillas M
    Eur J Cancer; 1992; 29A(1):57-60. PubMed ID: 1445746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study.
    Gertz MA; Kalish LA; Kyle RA; Hahn RG; Tormey DC; Oken MM
    Am J Clin Oncol; 1995 Dec; 18(6):475-80. PubMed ID: 8526187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of multiple myelomas resistant to alkylating agents by continuous vincristine-adriamycin perfusion and dexamethasone. Group for the Study and Research on Myelomas].
    Presse Med; 1986 Nov; 15(40):2001-4. PubMed ID: 2948170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents.
    Cornelissen JJ; Sonneveld P; Schoester M; Raaijmakers HG; Nieuwenhuis HK; Dekker AW; Lokhorst HM
    J Clin Oncol; 1994 Jan; 12(1):115-9. PubMed ID: 7903690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide.
    Hussein MA
    Oncologist; 2003; 8 Suppl 3():39-45. PubMed ID: 14671227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma.
    Dimopoulos MA; Weber D; Delasalle KB; Alexanian R
    Cancer; 1993 Nov; 72(9):2589-92. PubMed ID: 8402480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of refractory multiple myeloma with vincristine, adriamycin, and dexamethasone].
    Ma MX; Yiu JR; Wu SL
    Zhonghua Nei Ke Za Zhi; 1989 May; 28(5):267-9, 313. PubMed ID: 2805963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma.
    Glasmacher A; Haferlach T; Gorschlüter M; Mezger J; Maintz C; Clemens MR; Ko Y; Hahn C; Ubelacker R; Kleinschmidt R; Gieseler F
    Leukemia; 1997 Dec; 11 Suppl 5():S22-6. PubMed ID: 9436934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.
    Rifkin RM; Gregory SA; Mohrbacher A; Hussein MA
    Cancer; 2006 Feb; 106(4):848-58. PubMed ID: 16404741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
    Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma.
    Ross DM; To LB; Horvath N
    Intern Med J; 2004; 34(9-10):576-8. PubMed ID: 15482273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
    J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of multiple myeloma resistant to alkylating agents with dexamethasone, vincristine and adriamycin in continuous infusion].
    Monconduit M; Le Loët X; Bernard JF; Menard JF; Grosbois B; Michaux JL; De Gramont A; Laporte JP; Najman A; Jouet JP
    Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):477-9. PubMed ID: 3616472
    [No Abstract]   [Full Text] [Related]  

  • 36. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.
    Berenson JR; Crowley JJ; Grogan TM; Zangmeister J; Briggs AD; Mills GM; Barlogie B; Salmon SE
    Blood; 2002 May; 99(9):3163-8. PubMed ID: 11964279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.
    Alexanian R; Weber D; Anagnostopoulos A; Delasalle K; Wang M; Rankin K
    Semin Hematol; 2003 Oct; 40(4 Suppl 4):3-7. PubMed ID: 15015890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistant multiple myeloma treated with mitozantrone in combination with vincristine and dexamethasone (MOD).
    Phillips JK
    Eur J Haematol; 1989 Jan; 42(1):109-10. PubMed ID: 2914592
    [No Abstract]   [Full Text] [Related]  

  • 39. Irreversibility of drug resistance in VAD-refractory myeloma.
    Dimopoulos MA; Alexanian R
    Am J Hematol; 1992 Jun; 40(2):154-5. PubMed ID: 1585916
    [No Abstract]   [Full Text] [Related]  

  • 40. Alpha-interferon combination therapy of resistant myeloma.
    Alexanian R; Barlogie B; Gutterman J
    Am J Clin Oncol; 1991 Jun; 14(3):188-92. PubMed ID: 2031504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.